The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a ...
The U.S. Food and Drug Administration said it approved Vertex Pharmaceuticals’ Journavx for short-term pain that often ...
People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.
Police and Crime Commissioner Joy Allen has expressed support for Government plans to seek expert advice on reclassifying ketamine as a Class A drug ...
CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...
The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...
At a closed-door House Republican retreat Saturday morning, newly re-elected House Speaker Mike Johnson, R-La., said President-elect Donald Trump was in favor of passing a single reconciliation ...
Johnson & Johnson reported that Spravato treated over 100,000 patients in 77 countries worldwide, including roughly 80,000 in ...